首页> 外文OA文献 >PCV6 Modeling the Cardiovascular Effects of Switching Patients from Rosuvastatin to Atorvastatin

【2h】

PCV6 Modeling the Cardiovascular Effects of Switching Patients from Rosuvastatin to Atorvastatin

机译：PCV6模拟将患者从瑞舒伐他汀转换为阿托伐他汀的心血管效应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Folse H.; Schuetz C.A.; Rengarajan B.; Sternhufvud C.; Gandhi S.K.;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia [J] . BaysH.E., AvernaM., MajulC., The American Journal of Cardiology . 2013,第12期

机译：在原发性高胆固醇血症患者中加入阿托伐他汀与阿托伐他汀增效或改用瑞舒伐他汀相比依泽替米贝的疗效和安全性
2. Impact of Switching Treatment From Rosuvastatin to Atorvastatin on Rates of Cardiovascular Events [J] . Folse Henry, Sternhufvud Catarina, Schuetz C. Andy, Clinical therapeutics . 2014,第1期

机译：罗苏伐他汀对杂血管事件率对阿托伐他汀的影响
3. Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin [J] . JacobsonT.A., WertzD.A., KuznikA., Current medical research and opinion . 2013,第7期

机译：阿托伐他汀患者与从阿托伐他汀改用辛伐他汀的患者的心血管事件发生率
4. Comparison of the effects of rosuvastatin and atorvastatin on plasma lipids and cytokines in hyperlipidemic patients with type 2 Diabetes [C] . Yoshino G., Osonoi T., Saitou M International Congress on Coronary Artery Disease . 2011

机译：枸杞子和阿托伐他汀对2型糖尿病患者血浆脂质和细胞因子的影响的比较
5. Model-based approaches to characterize clinical pharmacokinetics of atorvastatin and rosuvastatin in disease state [D] . Macwan, Joyce S. 2013

机译：基于模型的方法表征疾病状态下阿托伐他汀和瑞舒伐他汀的临床药代动力学
6. Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies [O] . Jennifer G. Robinson, Helen M. Colhoun, Harold E. Bays, 2014

机译：Alirocumab作为高胆固醇血症患者（未充分用阿托伐他汀（20或40 mg）或瑞舒伐他汀（10或20 mg）控制的高胆固醇血症患者）的附加治疗的有效性和安全性：ODYSSEY OPTIONS研究的设计和原理
7. PCV6 A META-ANALYSIS OF EFFICACY OF ATORVASTATIN IN COMPARISON TO PRAVASTATIN, SIMVASTATIN AND ROSUVASTATIN FOR THE CONTROL OF DYSLIPIDEMIA AND CARDIOVASCULAR EVENTS PREVENTION [O] . Villasis-Keever MA, Rendón-Masías ME, Pineda-Cruz R, 2010

机译：PCV6与普伐他汀，辛伐他汀和罗伐他汀比较，阿托伐他汀与血脂异常和心血管疾病预防的功效的元分析

PCV6 Modeling the Cardiovascular Effects of Switching Patients from Rosuvastatin to Atorvastatin

著录项

引文网络

相似文献

相关主题

期刊订阅